Weight-loss-drug makers unveil new data and deals

Major pharmaceutical firms like Eli Lilly are advancing next-generation weight-loss molecules targeting GLP-1 and GIP receptors, building on current blockbusters like Zepbound and Mounjaro while seeking reduced side effects.